Skip to main content

Advertisement

Table 1 Patient background

From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

   N(%)
Age, year Median (range) 64.5 (37–78)
Sex Male 35 (83.3)
Female 7 (16.7)
PS 0 37 (88.1)
1 5 (11.9)
MSKCC prognostic risk Favorable 12 (28.6)
  Intermediate 28 (66.7)
  Poor 2 (4.8)
Histology Clear cell 42* (100)
Nephrectomy Yes 42 (100)
No 0  
Metastasis Lung 32 (76.2)
  Liver 5 (11.9)
  Pancreas 5 (11.9)
  Lymph node 4 (9.5)
  Bone 4 (9.5)
  1. *Including one case with spindle cell components 5 %